The rising incidence of cancer, negative side effects from the use of cancer medications, and a growth in the global elderly population, is expected to drive market expansion in the near future at a CAGR of 2.50% during the forecast period 2023 to 2032

Market Research Future (MRFR) has published on the "Cancer Supportive Care Market”

Cancer Supportive Care Market Highlights

The global cancer supportive care market is accounted to register a CAGR of 2.50% during the forecast period and is estimated to reach USD 24.9 billion by 2032.

A number of factors, such as the rising incidence of cancer, negative side effects from the use of cancer medications, and a growth in the global elderly population, have an impact on the market for cancer supportive care pharmaceuticals. The market for cancer supportive care drugs is growing as a result of rising government healthcare spending as well as increased usage of biosimilars. However, the increase of cancer supportive care pharmaceuticals may be constrained by the development of targeted therapy drugs with fewer side effects, which are rapidly being discovered and preferred by patients and physicians.

MRFR recognizes the following companies as the key players in the global Cancer Supportive Care market— Amgen Inc., Baxter International Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc (GSK) (Tesaro), Helsinn Healthcare, Heron Therapeutics, Johnson & Johnson (Janssen Global Services, LLC,), Merck KGAA, Novartis International AG (Sandoz), and Teva Pharmaceuticals.

Segment Analysis

The global cancer supportive care market has been segmented based type, application, and distribution channel.

On the basis of type, the market is segmented into ESA (erythropoiesis-stimulating agents), G-CSFs (granulocyte colony-stimulating factors), antiemetics, bisphosphonates, opioids, NSAIDs (non-steroidal auto inflammatory drugs). ), G-CSFs (granulocyte colony-stimulating factors) category sales accounted for the biggest revenue proportion in 2022. It serves as the main therapy for cancer-related neutropenia. One of the supportive care medications most frequently used to treat lymphoma and breast cancer is this one.

Based on application, the global Cancer Supportive Care market has been segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, stomach cancer, and others. The breast cancer category had the largest market share in 2022. The rise in female breast cancer incidence around the world is to blame for this.

Based on distribution channel, the global Cancer Supportive Care market has been segmented into hospital pharmacies, drug stores and retail pharmacies, and online providers. Hospital pharmacies category held the largest proportion of the market in 2022. The ability of the hospital pharmacy to offer patients individualized treatment regimens for cancer patients is what drives the segment's growth.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Cancer Supportive Care Market Research Report

Regional Analysis

The global Cancer Supportive Care market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Cancer Supportive Care market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Cancer Supportive Care market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Cancer Supportive Care market comprises of Middle East, Africa, and Latin America.

The largest market share for Cancer Supportive Care was maintained by the North American regional sector. The swift adoption of pharmaceutical industry developments is predicted to greatly expand the market for cancer supportive care drugs in North America.

Moreover, the Europe market has been persistently growing over the forecast period. Due to the sharp increase in female patients being diagnosed with breast cancer, there is a greater need in the area for palliative care services and cancer supportive care medications.

Additionally, Asia Pacific is anticipated to experience the quickest growth over the forecast period. This growth is a result of the rising need for supportive care in the cancer business. Chemotherapy is widely used to treat cancer patients in this area.

Furthermore, the rest of the world's Cancer Supportive Care market is divided into the Middle East, Africa, and Latin America. The market is primarily driven by the increasing prevalence of cancer and the growing demand for supportive care services and therapies to manage the symptoms and side effects of cancer treatments.

Key Findings of the Study

• The global Cancer Supportive Care market is expected to reach USD 24.9 billion by 2032, at a CAGR of 2.50% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to the rising need for supportive care in the cancer business


• Based on distribution channel, the Hospital pharmacies segment was attributed to holding the largest market in 2022, with an approximate market share of 45–65%.


• Amgen Inc., Baxter International Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc (GSK) (Tesaro), Helsinn Healthcare, Heron Therapeutics, Johnson & Johnson (Janssen Global Services, LLC,), Merck KGAA, Novartis International AG (Sandoz), and Teva Pharmaceuticals.